NMD4C Launch Canadian Neuromuscular Clinical Trial Database
The NMD4C are excited to launch the The Canadian Neuromuscular Clinical Trial Database to provide a comprehensive and reliable landscape of Canadian neuromuscular clinical trials. The trial database is an initiative of the NMD4C Clinical Trial Network (CTN) created in collaboration with Canadian neuromuscular clinical trial site teams. Monthly updates are provided by clinical research coordinators working at Canadian trial sites, ensuring the most current information is always available.
The Canadian Neuromuscular Clinical Trial Database has been designed to meet the needs of Canadian neuromuscular trial community stakeholders.
- Providing accurate and up-to-date information: Our database provides reliable details about recruiting and not yet recruiting neuromuscular clinical trials, including clinical trial site locations and contact information.
- Fostering collaboration: Enables investigators to identify other sites conducting the same trial at different locations, fostering collaboration to address challenges and share best practices,
- Streamlining patient referral: Can be used as a tool to facilitate patient referral to appropriate clinical trials and/or clinical sites.
The database will continue to be updated and expanded. If you have any questions about the Canadian Neuromuscular Clinical Trial Database or would like to add your site to our list, please contact CTN manager Dr. Maria Masnata.
The NMD4C CTN is led by Dr. Craig Campbell, Dr. Jean Mah, and Dr. Kerri Schellenberg, with the objectives of increasing the number of clinical trials in Canada, enhance Canadian sites’ trial capacity, and support a cohesive network of clinician researchers and their teams.
Read next...
Zolgensma® Safety Update and CPNG Guidance for Families
The Canadian Pediatric Neuromuscular Group (CPNG) has issued a statement for families regarding recent reports of tumours in children treated with Zolgensma® (onasemnogene abeparvovec) gene therapy for spinal muscular atrophy (SMA). The statement outlines current evidence, considerations for follow-up care, and information for families and healthcare providers.
Could You Be Our Next Awardee? Meet Jules Granet, NMD4C’s 2026 Publication of the Year Awardee
Nominations are open till by 18 January 2027!
In 2026, Jules Granet, a PhD Candidate at McGill University and trainee in Dr. Natasha Chang’s laboratory received an NMD4C Publication of the Year Award for research investigating how muscle stem cell dysfunction contributes to impaired muscle regeneration in Duchenne muscular dystrophy. Nominate yourself or a neuromuscular colleague whose research, clinical care, leadership, advocacy, or community contributions deserve to be recognized.
Early Bird Registration Now Open: 8th Ottawa International Conference On Neuromuscular Disease & Biology
We are happy to announce that early bird registration is now open for the 8th Ottawa International Conference On Neuromuscular Disease & Biology which will be held on October 14-16, 2027 at the Fairmont Château Laurier in Ottawa, Canada. Now under the leadership of NMD4C Investigators; Dr. Mireille Khacho, Dr. Hanns Lochmuller, Dr. Bernard Jasmin, and Dr. Rashmi Kothary.